 |
      
|
|
|
|
|
|||||
|
|
April 8, 2005
Neurochem unblinds the Phase II/III Clinical Study for Fibrillex™ in the treatment of
AA Amyloidosis. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug and a Fast Track Product candidate
and is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was recently concluded. 3-amino-1-propanesulfonic acid
(3APS; Alzhemed™), for the treatment of Alzheimer's Disease, is in a Phase III clinical trial and 3APS
(Cerebril™), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a
Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks disclosed in public filings of Neurochem.
Further, a delay in the process could be caused by a number of factors, including a delay in Neurochem receiving
the data; more time needed than expected to achieve the appropriate degree of analysis; or more time needed to
ensure quality control and that the statistical analysis complies with applicable regulations. Consequently, actual
future results may differ materially from the anticipated results expressed in the forward-looking statements. The
reader should not place undue reliance, if any, on the forward-looking statements included in this news release.
These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention
to update or revise such statements as a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
